[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know",
    "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=9f4f2d6785531f701cd67d697dd575c4b54b57c32d37219429eeb5e95bdcf476",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745444717,
      "headline": "Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know",
      "id": 134059561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=9f4f2d6785531f701cd67d697dd575c4b54b57c32d37219429eeb5e95bdcf476"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Declares Second-Quarter 2025 Dividend",
    "summary": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer.",
    "url": "https://finnhub.io/api/news?id=c406910066789c614acde8e3cd7486dc3d2c4ed5109fc80303822af10a2f6324",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745440800,
      "headline": "Pfizer Declares Second-Quarter 2025 Dividend",
      "id": 134059562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer.",
      "url": "https://finnhub.io/api/news?id=c406910066789c614acde8e3cd7486dc3d2c4ed5109fc80303822af10a2f6324"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Summit Therapeutics Stock Soaring On Wednesday?",
    "summary": "Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored",
    "url": "https://finnhub.io/api/news?id=d56e66b96b2b2d09005aa804c130270c8e3ebd5407f9df64b0581cbf3192bbe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745437663,
      "headline": "Why Is Summit Therapeutics Stock Soaring On Wednesday?",
      "id": 134048132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored",
      "url": "https://finnhub.io/api/news?id=d56e66b96b2b2d09005aa804c130270c8e3ebd5407f9df64b0581cbf3192bbe0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting",
    "summary": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary,",
    "url": "https://finnhub.io/api/news?id=e54e5a8302eb472adf312b71de80f1b840213bd5c10e85989f2428dd8204a3e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745437560,
      "headline": "Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting",
      "id": 134059564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary,",
      "url": "https://finnhub.io/api/news?id=e54e5a8302eb472adf312b71de80f1b840213bd5c10e85989f2428dd8204a3e5"
    }
  },
  {
    "ts": null,
    "headline": "Why vaccine makers aren't worried about Trump administration cuts",
    "summary": "Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.",
    "url": "https://finnhub.io/api/news?id=5f2281d05e91f5a68972135f1f2758d014a15dd528f8f9b0be26e5a5c974bcbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745434227,
      "headline": "Why vaccine makers aren't worried about Trump administration cuts",
      "id": 134046384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.",
      "url": "https://finnhub.io/api/news?id=5f2281d05e91f5a68972135f1f2758d014a15dd528f8f9b0be26e5a5c974bcbd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
    "summary": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
    "url": "https://finnhub.io/api/news?id=15b32c0c3a510d3b5de081085e51fc0a0343dcf4a6fe0cf9a3ff58cb7785db4a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745416353,
      "headline": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
      "id": 134045691,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=15b32c0c3a510d3b5de081085e51fc0a0343dcf4a6fe0cf9a3ff58cb7785db4a"
    }
  },
  {
    "ts": null,
    "headline": "3 of Wall Street’s Favorite Stocks Walking a Fine Line",
    "summary": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
    "url": "https://finnhub.io/api/news?id=360b2856912a1b95fa570b1bbdc96651cb6db4b4d68a3d7b12b02d59d43b4393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745413440,
      "headline": "3 of Wall Street’s Favorite Stocks Walking a Fine Line",
      "id": 134046569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
      "url": "https://finnhub.io/api/news?id=360b2856912a1b95fa570b1bbdc96651cb6db4b4d68a3d7b12b02d59d43b4393"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks to Buy for Passive Income",
    "summary": "Passive income is essential in retirement, but building a dependable stream isn't easy.  Fortunately, top-tier dividend stocks can do the heavy lifting.  In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.",
    "url": "https://finnhub.io/api/news?id=c5087b9e7c3359947d7679c8e68ea9b4d40a6e66cadba3b97a51ec62c48b861a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745411400,
      "headline": "2 High-Yield Dividend Stocks to Buy for Passive Income",
      "id": 134046318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Passive income is essential in retirement, but building a dependable stream isn't easy.  Fortunately, top-tier dividend stocks can do the heavy lifting.  In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.",
      "url": "https://finnhub.io/api/news?id=c5087b9e7c3359947d7679c8e68ea9b4d40a6e66cadba3b97a51ec62c48b861a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?",
    "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.",
    "url": "https://finnhub.io/api/news?id=c396b52d7302162746b65130960ca345593d6eaf5b1c6cd52bd4dd69de35f919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745405880,
      "headline": "Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?",
      "id": 134046571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.",
      "url": "https://finnhub.io/api/news?id=c396b52d7302162746b65130960ca345593d6eaf5b1c6cd52bd4dd69de35f919"
    }
  },
  {
    "ts": null,
    "headline": "What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?",
    "summary": "The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030.  As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.  Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill.",
    "url": "https://finnhub.io/api/news?id=bee2023ccd5ec798bd52709a469681f97e3a61f75cf5d53f17c904bfa86d98eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745404800,
      "headline": "What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?",
      "id": 134046572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030.  As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.  Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill.",
      "url": "https://finnhub.io/api/news?id=bee2023ccd5ec798bd52709a469681f97e3a61f75cf5d53f17c904bfa86d98eb"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys",
    "summary": "Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street.",
    "url": "https://finnhub.io/api/news?id=c0ccfab95970a9d74cc9ef84052dabc25a04e9473eb27d8e4281e4426a44ab31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745394660,
      "headline": "S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys",
      "id": 134046573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street.",
      "url": "https://finnhub.io/api/news?id=c0ccfab95970a9d74cc9ef84052dabc25a04e9473eb27d8e4281e4426a44ab31"
    }
  },
  {
    "ts": null,
    "headline": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
    "summary": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
    "url": "https://finnhub.io/api/news?id=eaac6e9c845c2f82b606d3d73abdf9f438e0115f65507451348e00074b95c29c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745379600,
      "headline": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
      "id": 134041757,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eaac6e9c845c2f82b606d3d73abdf9f438e0115f65507451348e00074b95c29c"
    }
  }
]